focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 21.50
Bid: 21.00
Ask: 22.00
Change: 0.00 (0.00%)
Spread: 1.00 (4.762%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 21.50
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

31 Jul 2020 16:31

RNS Number : 8003U
Renalytix AI PLC
31 July 2020
 

 

 

Renalytix AI plc

(the "Company") 

 

Total Voting Rights

 

For the purposes of DTR5.6.1R of the Transparency Directive, the Company notifies the market of the following:

 

As of 31 July 2020, the Company's issued and fully paid share capital consists of 72,029,634 ordinary shares with a nominal value of £0.0025 each ("Ordinary Shares"), with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. The total number of voting rights in the Company is therefore 72,029,634.

 

The above figure of 72,029,634 should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

 

 

For further information, please contact:

 

Renalytix AI plc 

www.renalytixai.com

James McCullough, CEO

Via Walbrook PR

Stifel (Nominated Adviser)

Tel: 020 7710 7600

Alex Price / Nicholas Moore

Walbrook PR Limited

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRFFLFXBDLEBBL
Date   Source Headline
13th Nov 20207:00 amRNSStifel 2020 Healthcare Conference
6th Nov 20207:00 amRNSChange of Adviser
2nd Nov 20203:30 pmRNSPosting of Annual Report & Accounts &Notice of AGM
28th Oct 20202:15 pmRNSRe-issued: EKF marketing & distribution agreement
27th Oct 20207:00 amRNSFull Year Report
20th Oct 202012:00 pmRNSSchedule One - Verici Dx PLC
16th Oct 20207:00 amRNSNotice of Results
13th Oct 20203:32 pmRNSVerici Dx - Intention to admit to trading on AIM
22nd Sep 20207:00 amRNSCalifornia Commercial Lab Certification Recieved
18th Sep 20207:00 amRNSKidneyIntelX clinical testing launch
2nd Sep 20207:00 amRNSGrant of Purchase Rights and Verici update
26th Aug 20207:00 amRNSSubmission seeking FDA Clearance of KidneyIntelX
21st Aug 20208:00 amRNSRenalytixAI to Collaborate with AstraZeneca
3rd Aug 20207:00 amRNSKidneyIntelX in Multi-Center Study
31st Jul 20204:31 pmRNSTotal Voting Rights
27th Jul 20207:00 amRNSOver allotment option exercise
21st Jul 20205:30 pmRNSClosing of Global Offering and resulting TVR
17th Jul 20207:00 amRNSPricing of Global Offering
13th Jul 202012:01 pmRNSLaunch of Global Offering and application to list
13th Jul 202011:45 amRNSResult of General Meeting
8th Jul 20207:01 amRNSApproval of distribution of shares in Verici Dx
8th Jul 20207:00 amRNSPartnership with America’s Choice Provider Network
7th Jul 20207:00 amRNSHolding(s) in Company
1st Jul 20207:00 amRNSKidneyIntelX study accepted for publication
30th Jun 20207:00 amRNSUniversity of Michigan Partnership & Data Sharing
25th Jun 20207:01 amRNSProposed Board changes; Circular & Notice of GM
25th Jun 20207:00 amRNSPublic filing re. Nasdaq dual-listing and offering
12th Jun 20207:00 amRNSKidneyIntelX™ receives New York State approval
10th Jun 20208:00 amRNSConfirmation of reduction of capital
10th Jun 20207:00 amRNSPositive results of clinical validation study
20th May 202011:06 amRNSSecond Price Monitoring Extn
20th May 202011:00 amRNSPrice Monitoring Extension
20th May 20207:00 amRNSJV for COVID-19 antibody test scaled production
18th May 20207:00 amRNSProposed dual-listing on Nasdaq
15th May 20201:02 pmRNSResult of General Meeting
5th May 202010:55 amRNSRemoval of US Securities Law Restrictions
28th Apr 20207:00 amRNSUpdate re. potential demerger of FractalDx
27th Apr 20207:00 amRNSUtah Lab Facility Achieves ISO 13485 Certification
20th Apr 20207:00 amRNSKidneyIntelX used in Mount Sinai COVID-19 study
15th Apr 20207:00 amRNSProvider network agreement for KidneyIntelX™
1st Apr 20207:00 amRNSMedicare provider number
27th Mar 202010:32 amRNSHolding(s) in Company
27th Mar 20207:00 amRNSPresentation of KidneyIntelX Health Economics Data
24th Mar 20207:00 amRNSPodium Presentation and Publication for Data
3rd Mar 20207:00 amRNSHalf-year Report
26th Feb 20207:00 amRNSNotice of Results
25th Feb 20207:00 amRNSConference attendance
8th Jan 20207:00 amRNSNew commercial testing facility opens in Utah
3rd Jan 20207:00 amRNSCMS Pricing Determination becomes effective
3rd Dec 20197:00 amRNSMedicare sets US national price for KidneyIntelX

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.